Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CLK1 | P49759 | 1/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.31 |
| ▸ | SPR | P35270 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7921137 | 0.80 | SLC9A1 (0.36) | SLC9A1KEAP1MAPTRAB9AHCAR3 | |
| SCHEMBL3513250 | 0.77 | HSD17B10 (0.44) | SLC9A1KEAP1MAPTHCAR3ATM | |
| SCHEMBL14085367 | 0.77 | MAPK14 (0.39) | HCAR3ATMCLK1DYRK1A | |
| SCHEMBL19836260 | 0.74 | HRH3 (0.37) | SLC9A1KEAP1MAPTRXRAGRIN1 | |
| SCHEMBL17694869 | 0.74 | PDE2A (0.35) | SLC9A1KEAP1 | |
| SCHEMBL14820272 | 0.74 | KDM4E (0.35) | SLC9A1KEAP1MAPTRAB9A | |
| SCHEMBL12890492 | 0.70 | BRD4 (0.36) | SLC9A1KEAP1MAPTRAB9A | |
| SCHEMBL14805639 | 0.70 | KDM4E (0.35) | SLC9A1KEAP1MAPTRAB9APOLB | |
| SCHEMBL18193686 | 0.70 | HSD17B10 (0.38) | MAPTRAB9ARXRAGRIN1GRIN2B | |
| SCHEMBL12775638 | 0.69 | ADA (0.39) | SLC9A1KEAP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080188478-A1 | Compounds Useful In Therapy | PFIZER INC. | 2008-08-07 | — | — | US | disclosed |
| WO-2006114706-A1 | TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | PFIZER LIMITED (GB) | 2006-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188478-A1 | Compounds Useful In Therapy | AVPR1A, AVPR1B, AVPR2 | SLC9A1 681/4885KEAP1 1082/4885MAPT 4528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.